Investment Rating - The report assigns a "Buy-A" investment rating with a 6-month target price of HKD 36.38 [4][6]. Core Insights - The company has shown a continuous narrowing of losses, with a reported loss of RMB 170 million for the year 2024. The core product, the LZ901 shingles vaccine, has made significant progress, completing the enrollment of 26,000 healthy participants in its Phase III clinical trial by January 2024. The mid-term analysis results of the trial are expected in the second half of 2024, and the BLA for LZ901 has been accepted by the NMPA, indicating promising commercialization prospects [1][2][4]. Summary by Sections Financial Performance - The company reported a loss of RMB 170 million for 2024, which is a reduction from previous losses. Revenue projections for 2025 to 2027 are estimated at RMB 0.02 billion, RMB 10.51 billion, and RMB 17.95 billion respectively, with net profits expected to be RMB -300 million, RMB 1.42 billion, and RMB 5.08 billion [4][9]. Product Pipeline - The company has a diverse product pipeline, including three candidates in clinical stages and six in preclinical stages. The core product LZ901 is complemented by a biosimilar of adalimumab (K3) expected to enter Phase III trials in 2026, and other candidates targeting various diseases [3][4]. Market Positioning - LZ901 is positioned competitively with a unique tetrameric molecular structure that enhances immunogenicity, leading to higher neutralizing antibody titers compared to Shingrix. The expected retail price for LZ901 is between RMB 500 to 800 per dose, significantly lower than Shingrix, which is priced at approximately RMB 3,200 for two doses [2][4]. Valuation Model - The report utilizes a DCF valuation model, projecting a target price of HKD 36.38 based on expected revenue growth and profitability improvements over the next few years [4][11].
绿竹生物-B（02480）：各管线进展加速，LZ901商业化可期